Marker Therapeutics Report issue

For profit Phase 1 Phase 2
Founded: Minneapolis MN United States (2015)

Organization Overview

First Clinical Trial
2020
NCT04511130
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Marker Therapeutics | Marker Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (7)

Key: Marker Therapeutics (1) Acquired (6)

cyclophosphamide (cytoxan) (1 trial)

durvalumab (imfinzi) (1 trial)

fralpha peptide (1 trial)

fralpha vaccine (1 trial)

mt-401 (1 trial)

sargramostim (leukine) (1 trial)

tpiv200 (1 trial)

Drugs in Phase 1 Trials (1)

Key: Marker Therapeutics (0) Acquired (1)

her-2/neu peptide vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 8